ArticleAesthetic plastic surgery2026
Cutaneous Sensory Alterations After Lower Limb Liposuction for Lipedema: A Comparative Study with Aesthetic Liposuction Patients.
Article in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLiposuction is effective for body contouring but may cause transient cutaneous sensory changes. In lipedema, therapeutic liposuction involves higher aspirate volumes, fibrotic tissue, and exposure of distal-leg zones at risk. We hypothesized that postoperative sensory alterations are more frequent and persistent after lipedema surgery than after aesthetic lower-leg liposuction, with disease severity-rather than technique-driving outcomes. MATERIALS AND
methodsIn this prospective, single-center cohort (January 2023-March 2024), 90 women underwent lower-leg liposuction (knee-to-ankle) by one surgeon: Control (aesthetic; n = 30), lipedema Stage I (n = 20), Stage II (n = 20), Stage III (n = 20). All procedures used VASER-assisted emulsification and MicroAire PAL aspiration under standardized tumescent infiltration. Sensory testing (Semmes-Weinstein monofilaments, thermal discrimination, pinprick, 10-point VAS) was performed at baseline and 1, 3, 6, and 12 months. Persistent alteration was defined as > 6 months. Satisfaction was assessed at 6 and 12 months with the BODY-Q Lower Leg module and a functional questionnaire. Logistic regression identified predictors of 12-month hypoesthesia. DISCUSSION: Aspirated volume increased with disease stage (Control 2400 mL; Stage I 2600 mL; Stage II 3500 mL; Stage III 4600 mL; p < 0.01) and correlated with persistent hypoesthesia/paresthesia (p < 0.01). Twelve-month hypoesthesia was seen in 3.3% (Control), 5% (Stage I), 15% (Stage II), and 25% (Stage III). Despite this, satisfaction was high across groups (BODY-Q: Control 90, Stage I 91, Stage II 88, Stage III 86). Lipedema patients also reported substantial improvements in pain (85-95%), mobility (80-92%), heaviness (88-96%), and bruising (78-91%). These findings indicate that advanced disease, not surgical method, accounts for prolonged sensory alterations.
conclusionLower-leg liposuction in lipedema provides significant symptomatic and functional relief, with consistently high satisfaction despite persistent sensory changes in Stage II-III disease. Disease severity and aspirated volume, not technique, are the main determinants of postoperative hypoesthesia. Counseling should balance sensory risk with the strong likelihood of life-changing benefits. LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
41291075What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.